Anti-lymphoma effects of mono/combination therapy with anti-CD20 and anti-HL-DR mabs in human lymphoma cell lines

被引：0
|
作者：
DeNardo, G [1 ]
Tobin, E [1 ]
Chan, K [1 ]
Bradt, B [1 ]
DeNardo, S [1 ]
机构：
[1] Univ Calif Davis, Med Ctr, Davis, CA 95616 USA
来源：
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2004年 / 19卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3
引用
收藏
页码：512 / 513
页数：2
相关论文
共 50 条
  • [1] Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines
    Tobin, Evan
    Denardo, Gerald
    Zhang, Nan
    Epstein, Alan L.
    Liu, Cathy
    DeNardo, Sally
    LEUKEMIA & LYMPHOMA, 2007, 48 (05) : 944 - 956
  • [2] Mechanisms of anti-lymphoma effects of the humanized anti-CD22 monoclonal antibody, epratuzumab, and combination studies with anti-CD20 MAbs.
    Stein, R
    Qu, ZX
    Chen, S
    Rosario, A
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    BLOOD, 2003, 102 (11) : 298B - 299B
  • [3] Anti-lymphoma activity of a new humanized anti-CD20 monoclonal antibody, hA20
    Goldenberg, DM
    On, ZX
    Horak, ID
    Hansen, H
    Stein, R
    FASEB JOURNAL, 2003, 17 (07): : C123 - C123
  • [4] Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
    Kohrt, Holbrook E.
    Thielens, Ariane
    Marabelle, Aurelien
    Sagiv-Barfi, Idit
    Sola, Caroline
    Chanuc, Fabien
    Fuseri, Nicolas
    Bonnafous, Cecile
    Czerwinski, Debra
    Rajapaksa, Amanda
    Waller, Erin
    Ugolini, Sophie
    Vivier, Eric
    Romagne, Francois
    Levy, Ronald
    Blery, Mathieu
    Andre, Pascale
    BLOOD, 2014, 123 (05) : 678 - 686
  • [5] Mechanisms of anti-lymphoma effects of a new humanized anti-CD20 monoclonal antibody, IMMU-106.
    Stein, R
    Hayes, M
    Qu, ZX
    Chen, S
    Rosario, A
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    BLOOD, 2003, 102 (11) : 298B - 298B
  • [6] Effects of combined therapy with gemcitabine and the anti-CD20 monoclonal antibody rituximab on human lymphoma cell lines.
    Joshi, I
    Jin, F
    Obasaju, C
    Smith, MR
    BLOOD, 2002, 100 (11) : 308B - 308B
  • [7] Anti-lymphoma effects and mechanisms of action of epratuzumab in cell lines and human xenografts
    Stein, R.
    Cardillo, T. M.
    Qu, Z.
    Hansen, H. J.
    Goldenberg, D. M.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2006, 21 (04) : 404 - 405
  • [8] Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma
    Lim, Sean H.
    Levy, Ronald
    JOURNAL OF IMMUNOLOGY, 2014, 193 (04): : 1519 - 1524
  • [9] Anti-CD20 (rituximab) in follicular lymphoma
    McLaughlin, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S51 - S51
  • [10] Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab
    Goldenberg, D. M.
    Chang, C.
    Rossi, E. A.
    Cardillo, T. M.
    Wegener, W. A.
    Teoh, N.
    Leonard, J. P.
    Fayad, L. E.
    Coiffier, B.
    Morschhauser, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345